{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:14:44Z","timestamp":1789600484182,"version":"build-2803163510"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":149,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Finerenone, a highly selective non-steroidal mineralocorticoid receptor antagonist, was approved for the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (diabetic kidney disease, DKD). Finerenone reduced the composite endpoint of heart failure events and cardiovascular death in patients with heart failure with preserved or mildly reduced ejection fraction (HFpEF\/HFmrEF). This study aimed to investigate the safety and cardiac effects of finerenone in patients with DKD with or without HFpEF\/HFmrEF in a real-world setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with DKD were prospectively enrolled and were treated with finerenone according to best clinical practice. Clinical, laboratory and echocardiographic assessments were performed before, 4 weeks and 6 months after starting finerenone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-one patients with DKD were included. At baseline, patients had a typical risk profile with arterial hypertension (90.3%) and hyperlipoproteinemia (87.1%). Most patients were treated with a sodium-glucose cotransporter 2 (SGLT2) inhibitor (93.5%). Treatment with finerenone was safe and well tolerated: after 4 weeks, the glomerular filtration rate decreased slightly from 52 (43\u201378) mL\/min\/1.73 m2 to 48.0 (39.0\u201371.0) mL\/min\/1.73 m2 (P = 0.002 vs. baseline), but stabilized thereafter. Similarly, the median potassium value increased from 4.2 (3.8\u20134.5) mmol\/L to 4.4 (4.2\u20134.8) mmol\/L (P = 0.017) after 4 weeks, but remained stable thereafter [4.4 (4.1\u20134.6) mmol\/L (P = 0.079)]. Only one patient (3.2%) had an unplanned hospitalization and concomitant hyperkalaemia up to 6.0 mmol\/L. HFpEF\/HFmrEF was frequently found in patients with DKD (71.0%), although most patients had a rather early stage with only mild symptoms and a median N-terminal pro B-type natriuretic peptide (NT-proBNP) value of 150.8 (54.5\u2013325.7) ng\/L. During treatment with finerenone, NT-proBNP and left ventricular mass index (LVMI) remained stable. In contrast, left atrial volume index (LAVI) decreased from baseline [31.2 (26.8\u201339.7) mL\/m2] to 4 weeks follow-up [29.7 (20.8\u201333.6) mL\/m2, P = 0.027] and decreased further after 6 months [26.6 (20.8\u201334.9) mL\/m2, P = 0.029]. In the subgroup of patients with HFpEF\/HFmrEF, E\/e\u2032 decreased from 11.9 (8.7\u201314.5) at baseline to 9.9 (8.0\u201312.4) after 6 months (P = 0.043).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In a real-world setting, treatment with finerenone is safe and well-tolerated in patients with DKD and may improve functional and structural cardiac parameters. Further investigation is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.15424","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T03:29:40Z","timestamp":1758598180000},"page":"4219-4229","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Finerenone in Diabetic Chronic Kidney Disease\u2014Real-World Insights Including Patients with HFpEF or HFmrEF"],"prefix":"10.1093","volume":"12","author":[{"given":"Kristian","family":"Hellenkamp","sequence":"first","affiliation":[{"name":"Department of Cardiology and Pneumology, University Medical Centre G\u00f6ttingen , G\u00f6ttingen ,","place":["Germany"]},{"name":"DZHK (German Centre for Cardiovascular Research), partner site G\u00f6ttingen , G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Kaebe","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, University Medical Centre G\u00f6ttingen , G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslava","family":"Valentova","sequence":"additional","affiliation":[{"name":"DZHK (German Centre for Cardiovascular Research), partner site G\u00f6ttingen , G\u00f6ttingen ,","place":["Germany"]},{"name":"Department of Geriatrics, University Medical Centre G\u00f6ttingen , G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"von Haehling","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Pneumology, University Medical Centre G\u00f6ttingen , G\u00f6ttingen ,","place":["Germany"]},{"name":"DZHK (German Centre for Cardiovascular Research), partner site G\u00f6ttingen , G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fani","family":"Delistefani","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, University Medical Centre G\u00f6ttingen , G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Gollisch","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, gastrointestinal Oncology and Endocrinology, University Medical Centre G\u00f6ttingen , G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Raddatz","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, gastrointestinal Oncology and Endocrinology, University Medical Centre G\u00f6ttingen , G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Kathrin","family":"Sch\u00e4fer","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, University Medical Centre G\u00f6ttingen , G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Koziolek","sequence":"additional","affiliation":[{"name":"DZHK (German Centre for Cardiovascular Research), partner site G\u00f6ttingen , G\u00f6ttingen ,","place":["Germany"]},{"name":"Department of Nephrology and Rheumatology, University Medical Centre G\u00f6ttingen , G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Wallbach","sequence":"additional","affiliation":[{"name":"DZHK (German Centre for Cardiovascular Research), partner site G\u00f6ttingen , G\u00f6ttingen ,","place":["Germany"]},{"name":"Department of Nephrology and Rheumatology, University Medical Centre G\u00f6ttingen , G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"key":"2026021804215926300_ehf215424-bib-0001","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2026021804215926300_ehf215424-bib-0002","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2026021804215926300_ehf215424-bib-0003","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2026021804215926300_ehf215424-bib-0004","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2026021804215926300_ehf215424-bib-0005","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2026021804215926300_ehf215424-bib-0006","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"2026021804215926300_ehf215424-bib-0007","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"2026021804215926300_ehf215424-bib-0008","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1681\/ASN.2022020207","article-title":"Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized crossover clinical trial","volume":"33","author":"Provenzano","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2026021804215926300_ehf215424-bib-0009","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/eurheartj\/ehaa758","article-title":"The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart \u2018OMics\u2019 in AGEing (HOMAGE) randomized clinical trial","volume":"42","author":"Cleland","year":"2021","journal-title":"Eur Heart J"},{"key":"2026021804215926300_ehf215424-bib-0010"},{"key":"2026021804215926300_ehf215424-bib-0011","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"2026021804215926300_ehf215424-bib-0012","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s00392-024-02396-4","article-title":"Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment","volume":"113","author":"von Haehling","year":"2024","journal-title":"Clin Res Cardiol"},{"key":"2026021804215926300_ehf215424-bib-0013","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/ehf2.14511","article-title":"Association of mild kidney dysfunction with diastolic dysfunction and heart failure with preserved ejection fraction","volume":"11","author":"Vernooij","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026021804215926300_ehf215424-bib-0014","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"key":"2026021804215926300_ehf215424-bib-0015","volume-title":"Kerendia: EPAR - Product Information"},{"key":"2026021804215926300_ehf215424-bib-0016","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/ejhf.3024","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"26","author":"Authors\/Task Force Members","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026021804215926300_ehf215424-bib-0017","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1038\/s41591-024-03264-4","article-title":"Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes","volume":"30","author":"Vaduganathan","year":"2024","journal-title":"Nat Med"},{"key":"2026021804215926300_ehf215424-bib-0018","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1038\/s41440-019-0320-9","article-title":"Does the temporary decrease in the estimated glomerular filtration rate (eGFR) after initiation of mineralocorticoid receptor (MR) antagonist treatment lead to a long-term renal protective effect?","volume":"42","author":"Sato","year":"2019","journal-title":"Hypertens Res"},{"key":"2026021804215926300_ehf215424-bib-0019","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/S2213-8587(14)70194-9","article-title":"Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial","volume":"2","author":"Ando","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026021804215926300_ehf215424-bib-0020","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial","volume":"309","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"key":"2026021804215926300_ehf215424-bib-0021","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/s0735-1097(97)00344-6","article-title":"Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures","volume":"30","author":"Nagueh","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"2026021804215926300_ehf215424-bib-0022","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/ejhf.2726","article-title":"Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials","volume":"25","author":"Ferreira","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026021804215926300_ehf215424-bib-0023","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"2026021804215926300_ehf215424-bib-0024","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1161\/CIRCHEARTFAILURE.115.002249","article-title":"Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone","volume":"8","author":"Shah","year":"2015","journal-title":"Circ Heart Fail"},{"key":"2026021804215926300_ehf215424-bib-0025","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"2026021804215926300_ehf215424-bib-0026","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/ehf2.14962","article-title":"Finerenone and left ventricular hypertrophy in chronic kidney disease and type 2 diabetes","volume":"12","author":"Filippatos","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026021804215926300_ehf215424-bib-0027","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1093\/eurjhf\/hfp112","article-title":"Independent relationship of left atrial size and mortality in patients with heart failure: an individual patient meta-analysis of longitudinal data (MeRGE heart failure)","volume":"11","author":"Rossi","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"2026021804215926300_ehf215424-bib-0028","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1161\/CIRCHEARTFAILURE.114.001276","article-title":"Left atrium in heart failure with preserved ejection fraction: structure, function, and significance","volume":"7","author":"Rossi","year":"2014","journal-title":"Circ Heart Fail"},{"key":"2026021804215926300_ehf215424-bib-0029","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1002\/ejhf.2562","article-title":"Left atrial disease and left atrial reverse remodelling across different stages of heart failure development and progression: a new target for prevention and treatment","volume":"24","author":"Inciardi","year":"2022","journal-title":"Eur J Heart Fail"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/6\/4219\/66968152\/eschf_12_6_4219.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/6\/4219\/66968152\/eschf_12_6_4219.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T09:22:07Z","timestamp":1771406527000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/12\/6\/4219\/8488212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":29,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,9,22]]},"published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.15424","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,9,22]]},"assertion":[{"value":"2025-08-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}